Ferhat IŞIK, Ümit İNCİ, Abdurrahman AKYÜZ, Burhan ASLAN, Murat ÇAP, İlyas KAYA, Mehmet Şahin ADIYAMAN, Önder BİLGE, Rojhat ALTINDAĞ, Derya Deniz ALTINTAŞ, Bernas ALTINTAŞ

The Impact of Hydroxychloroquine with or without Azithromycin Treatment on T-peak to T-end Time in Patients Hospitalized with Coronavirus Disease (COVID-19)

INTRODUCTION: The aim of our study is to investigate the effects of hydroxychloroquine (HCQ) with azithromycin (AZR) treatment versus HCQ alone on T-endto T-peak (TpTe) time in COVID-19 patients. METHODS: Two hundred-five consecutive patients hospitalized with the diagnosis of COVID-19 were included in our study. Patients were divided into two groups according to the HCQ alone and HCQ+AZR combination treatments administered. These two groups were compared according to the demographic features, admission and follow-up laboratory parameters, admission and 3rd day electrocardiographic (ECG) parameters. RESULTS: The median age of all patients was 44 (31-59) and 53% of them were male. QRS interval, QT interval, QTc interval, QT dispersion, QTc dispersion,TpTe time and TpTe/QTc ratio were significantly higher in the 3rd day ECGs than admission ECGs. In the HCQ group, QT dispersion and QTc dispersion at admission ECG were significantly higher than in the HCQ + AZR group. On the 3rd day ECG parameters of the two groups were similar. We determined the predicting factors of theTpTe time on the 3rd day ‘s ECG using linear regression analysis. These were the HCQ+ AZR combination treatment [regression coefficient (RE) 0.097 and 95% CI 0.960, 4.109, p = 0.040], female gender (RE -0.119 and 95% CI -4.552, -0.440, p = 0.018), and TpTe time at admission ECG (RE 0.741 and 95% CI 0.637, 0.840, p < 0.001). DISCUSSION AND CONCLUSION: HCQ + AZR combination treatment was found to be an independent predictor in the prolongation of theTpTe time, compared to the HCQ alone treatment.

COVİD-19 Tanısı ile Yatırılan Hastalarda Hidroksiklorokin ve/veya Azitromisin Tedavisinin T tepe-T bitiş Süresi Üzerine Olan Etkisi

GİRİŞ ve AMAÇ: Çalışmamızın amacı COVİD-19 hastalarında hidroksiklorokin (HQC) ve azitromisin (AZR) tedavisinin, sadece hidroksiklorokin (HCQ) alan hastalara göre T tepe-T bitiş (TpTe) süresi üzerine etkilerini araştırmaktır. YÖNTEM ve GEREÇLER: Çalışmamıza 6 Nisan-30 Nisan 2020 tarihleri arasında COVİD-19 tanısı ile yatırılan ardışık 205 hasta alındı. Hastalar, yalnız HQC verilen ve HQC+AZR kombinasyonu verilenler diye iki gruba ayrıldı. İki grup demografik özellikleri, başvuru ve 3.gün laboratuar parametreleri ve 3.gün elektrokardiografi (EKG) bulgularına göre karşılaştırıldı. Ayrıca tüm hastaların başvuru ve 3.gün EKG’leri karşılaştırıldı. BULGULAR: Tüm hastaların median yaş ortalaması 44 (31- 59) olup, % 53’ü erkek hastalardı. Hastaların başvuru EKG’sine göre 3.gün EKG’ lerinde; QRS süresi, QT süresi, QTc süresi, QT dispersiyonu, QTc dispersiyonu, TpTe süresi ve TpTe/QTc oranı anlamlı olarak daha fazlaydı. HQC grubunda HQC+AZR grubuna göre, başvuru EKG'lerinde QT dispersiyonu ve QTc dispersiyonu anlamlı olarak daha fazlaydı. İki grubun 3. gün EKG parametreleri ise benzerdi. Lineer regresyon analizi yöntemini kullanarak 3.gün EKG'lerindeki TpTe değerleri için bazı prediktörler tespit ettik. Bunlar; HCQ+AZR kombinasyonunun kullanılması [regressioncoefficient (RE) 0.097 and 95% CI 0.960, 4.109, p = 0.040], kadın cinsiyet (RE -0.119 and 95% CI -4.552, -0.440, p = 0.018) ve başvuru EKG'sindeki TpTe süresi (RE 0.741 and 95% CI 0.637, 0.840, p < 0.001) idi. TARTIŞMA ve SONUÇ: Çalışmamız sonucunda, HQC+AZR kombinasyon tedavisinin HQC grubuna karşı TpTe süresinin uzamasında bağımsız bir prediktör olduğu görülmüştür.

PDF

___

1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al, Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 Feb 7. [Epub ahead of print], doi: 10.1001/jama.2020.1585.

2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7.

3. Naming the coronavirus disease (COVID-19) and the virus that causes it [Internet]. [cited 2020 Mar 21]. Available at: https://www.who.int/emergencies/diseases/n ovel-coronavirus-2019/technical guidance/naming-the-coronavirus-disease- (covid-2019)-and-the-virus that-causes-it. Accessed Mar 23, 2020.

4. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquinefor the treatment of COVID-19. J Crit Care. 2020 Mar 10. doi: 10.1016/j.jcrc.2020.03.005.

5. Guatret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinicaltrial. Int Journal of Antimi Agents. 2020 Jul;56(1): 105949. doi: 10.1016/j.ijantimicag.2020.105949.

6. Rickham, PP. (1964). Human experimentation. Code of ethics of the World Medical Association. Declaration of Helsinki. Br. Med. J, 2(5402):177.

7. Castro JH, Antzelevitch C, Tornés Bárzaga F, et al. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol. 2006;47(9):1828–34. doi: 10.1016/j.jacc.2005.12.049.

8. WHO Disease Outbreak News, https://www.who.int/csr/don/en/ Novel Coronavirus disease.

9. Luigi X Cubeddu. Drug-induced Inhibition and Trafficking Disruption of Ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr. cardilogy rewiev 2016;12(2):141-54.doi: 10.2174/1573403x12666160301120217.

10. Timothy F. Simpson, Richard J. Et al. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. American College of Cardiology. 2020 Mar 29.

11. Pukrittayakamee S, Tarning J, Jittamala P, et al. Pharmacokinetic interactions between primaquine and chloroquine. Antimicrob Agents Chemother. 2014;58(6):3354-9. doi: 10.1128/AAC.02794-13.

12. Mzayek F, Deng H, Mather FJ, et al. Randomized döşe ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials. 2007 Jan 5;2(1): e6. doi: 10.1371/journal.pctr.0020006.

13. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ et al, Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19), JAMA Cardiol. doi:10.1001/jamacardio. 2020.1834.

14. Macfarlane PW, McLaughlin SC, Rodger JC. Influence of lead selection and population on automated measurement of QT dispersion. Circulation 1998 Nov 17;98(20):2160-7. doi: 10.1161/01.cir.98. 20.2160.

15. Karjalainen L. Viitasalo M, Manttari M, Manninen V: Relation between QT interval and heart rates from 40 to 120 beats/ min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 1994 Jun;23(7):1547-53. doi: 10.1016/0735-1097(94)90654-8.

16. Ragesh P., Kyndaron R., Audrey UyEvanado et al. Prolonged Tpeak-to-Tend Interval on the Resting ECG Is Associated With Increased Risk of Sudden Cardiac Death, Circ Arrhythm Electrophysiol. 2011 Aug;4(4):441-7. doi: 10.1161/CIRCEP.110. 960658.

17. Erikssen G, Liestøl K, Gullestad L, Haugaa KH, Bendz B, Amlie JP. The terminal part of the QT interval (T peakto T end): a predictor of mortality after acute myocardial infarction. Ann Non invasive Electrocardiol 2012 Apr;17(2):85-94. doi: 10.1111/j.1542- 474X.2012.00493.x.

18. Zhao X, Xie Z, Chu Y, Yang L, Xu W, Yang X, et al. Association between Tp-e/QT ratio and prognosis in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Clin Cardiol 2012 Sep;35(9):559- 64. doi: 10.1002/clc.22022.

19. Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol. 2008;41(6):567–574. doi: 10.1016/j.jelectrocard.2008.07.016.

20. Yan GX, Wu Y, Liu T, Wang J, Marinchak RA, Kowey PR. Phase 2 early after depolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 2001;103:2851-56. https://doi.org/10. 1161/01.CIR.103.23.2851

21. Yan GX, Martin J. Electrocardiographic T wave: a symbol of transmural dispersion of repolarization in the ventricles. J Cardiovasc Electrophysiol 2003 Jun;14(6):639-40. doi: 10.1046/j.1540-8167.2003.03155.x.

22. Antzelevitch C, Sicouri S, Litovsky SH, Lukas A, Krishnan SC, Di Diego JM, Gintant GA, Liu DW. Heterogeneity with in the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. CircRes. 1991 Dec;69(6):1427- 49. doi: 10.1161/01.res.69.6.1427.

23. Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2024-38. doi: 10.1152/ajpheart.00355.2007.

24. Liu T, Brown BS, Wu Y, Antzelevitch C, Kowey PR, Yan GX. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm. 2006; 3(8): 948–956. doi: 10.1016/j.hrthm.2006.04.021.

25. Yan GX, Antzelevitch C. Cellular basisforthe normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation. 1998;98: 1928 -1936. https://doi.org/10.1161/01.CIR. 98.18.1928.

26. Antzelevitch C, Shimizu W, Yan GX, Sicouri S, Weissenburger J, Nesterenko VV, Burashnikov A, Di Diego J, Saffitz J, Thomas GP. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol. 1999 Aug;10(8):1124-52. doi: 10.1111/j.1540-8167.1999.tb00287.x.

27. Watanabe N, Kobayashi Y, Tanno K, Miyoshi F, Asano T, Kawamura M, et al, Transmural dispersion of repolarization and ventricular tachyarrhythmias. J Electrocardiol. 2004 Jul;37(3):191-200. doi: 10.1016/j.jelectrocard.2004.02.002.